Table 4 Treatment-emergent adverse events occurring in ≥ 5% of patients in the overall period (SAF)
| Total (N = 843) n (%) | |
|---|---|
| Nasopharyngitis | 335 (39.7) |
| Rheumatoid arthritis | 105 (12.5) |
| Herpes zoster | 99 (11.7) |
| Influenza | 80 (9.5) |
| Bronchitis | 68 (8.1) |
| Blood creatine phosphokinase increased | 66 (7.8) |
| Contusion | 59 (7.0) |
| Hypertension | 57 (6.8) |
| Pharyngitis | 56 (6.6) |
| Dental caries | 51 (6.0) |
| Upper respiratory tract infection | 51 (6.0) |
| Constipation | 49 (5.8) |
| Cystitis | 47 (5.6) |
| Gastroenteritis | 47 (5.6) |
| Back pain | 42 (5.0) |
| Cough | 42 (5.0) |
